Cyclo (CRVIIF)
Cyclo CRVIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains KD of 65 and 123 μM, respectively[1].
Product Specifications
UNSPSC
12352209
Target
HIF/HIF Prolyl-Hydroxylase
Type
Peptides
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cyclo-crviif.html
Solubility
10 mM in DMSO
Smiles
O=C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@@H](C)CC)C(N[C@H]1CC2=CC=CC=C2)=O)=O)=O)=O)[C@H](CS)NC1=O
Molecular Formula
C35H57N9O6S
Molecular Weight
731.95
References & Citations
[1]Ball AT, et al., Identification and Development of Cyclic Peptide Inhibitors of Hypoxia Inducible Factors 1 and 2 That Disrupt Hypoxia-Response Signaling in Cancer Cells. J Am Chem Soc. 2024 Mar 19.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
HIF
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
AAF-444-1 1 mL
Alkaline Phosphatase Conjugated Goat Affinity Purified Antibody to Mouse IgG + IgM (min.x Hu., Bov., Eq.)
Sign In for Pricing
View Details